lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in
Company profile
Ticker
LIXT
Exchange
Website
CEO
John S. Kovach
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SRKP 7 INC
SEC CIK
Corporate docs
Subsidiaries
Lixte Biotechnology, Inc. ...
LIXT stock data
Latest filings (excl ownership)
S-3
Shelf registration
23 Apr 24
8-K
Other Events
27 Mar 24
8-K
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
22 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Professor René Bernards to Present New Pre-Clinical Data
27 Feb 24
8-K
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
26 Feb 24
8-K
Other Events
30 Jan 24
8-K
Departure of Directors or Certain Officers
28 Nov 23
8-K
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
13 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Latest ownership filings
4
der Baan Bastiaan Jeroen van
16 Oct 23
4/A
Rene Bernards
5 Oct 23
4
der Baan Bastiaan Jeroen van
5 Oct 23
4
Rene Bernards
4 Oct 23
4
der Baan Bastiaan Jeroen van
27 Sep 23
4
der Baan Bastiaan Jeroen van
7 Jul 23
4
Yun Yen
7 Jul 23
4
Regina Brown
7 Jul 23
4
Stephen J. Forman
7 Jul 23
4/A
der Baan Bastiaan Jeroen van
5 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.11 mm | 5.11 mm | 5.11 mm | 5.11 mm | 5.11 mm | 5.11 mm |
Cash burn (monthly) | (no burn) | 121.35 k | 341.39 k | 474.75 k | 314.80 k | 383.30 k |
Cash used (since last report) | n/a | 826.45 k | 2.33 mm | 3.23 mm | 2.14 mm | 2.61 mm |
Cash remaining | n/a | 4.28 mm | 2.78 mm | 1.87 mm | 2.96 mm | 2.50 mm |
Runway (months of cash) | n/a | 35.3 | 8.1 | 3.9 | 9.4 | 6.5 |
Institutional ownership, Q2 2023
6.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 108.75 mm |
Total shares | 135.77 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Warberg Asset Management | 53.18 k | $3.71 mm |
Ethos Financial | 42.11 k | $3.63 mm |
Clear Street | 23.15 k | $2.00 k |
Geode Capital Management | 10.12 k | $58.99 mm |
MS Morgan Stanley | 7.11 k | $41.78 mm |
UBS UBS Group AG - Registered Shares | 101.00 | $594.00 k |
Tower Research Capital | 8.00 | $47.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Oct 23 | der Baan Bastiaan Jeroen van | Common Stock | Buy | Acquire P | No | No | 2.8 | 10,000 | 28.00 k | 11,000 |
3 Oct 23 | Rene Bernards | Common Stock | Buy | Acquire P | No | No | 2.51 | 5,527 | 13.87 k | - |
3 Oct 23 | Rene Bernards | Common Stock | Buy | Acquire P | No | No | 2.51 | 5,527 | 13.87 k | 25,000 |
2 Oct 23 | Rene Bernards | Common Stock | Buy | Acquire P | No | No | 2.29 | 4,473 | 10.24 k | - |
2 Oct 23 | Rene Bernards | Common Stock | Buy | Acquire P | No | No | 2.29 | 4,473 | 10.24 k | 19,473 |
26 Sep 23 | der Baan Bastiaan Jeroen van | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 1.95 | 250,000 | 487.50 k | 250,000 |
26 Sep 23 | der Baan Bastiaan Jeroen van | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 1.95 | 250,000 | 487.50 k | 250,000 |
30 Jun 23 | der Baan Bastiaan Jeroen van | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 5.88 | 10,000 | 58.80 k | 10,000 |
17 Jun 22 | der Baan Bastiaan Jeroen van | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 7.4 | 25,000 | 185.00 k | 25,000 |
News
Watching Lixte Biotechnology; White Diamond Research Posts On X "BREAKING NEWS: Lixte Biotechnology Lied: Its Publication Yesterday Isn't New – It's The Same One They Published Over A Year Ago"
28 Mar 24
Gold Moves Higher; Velo3D Shares Plummet
27 Mar 24
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
27 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
27 Mar 24
Crude Oil Edges Lower; PaySign Shares Spike Higher
27 Mar 24